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Abstract
Objective: This study was conducted to assess pharmacists’ practices when counseling patients on their prescription medications, and
their preferences for training.
Methods: Five focus group discussions of community pharmacists (n=45, with seven to eleven participants in each group) were
conducted in a major metropolitan city in the southern United States. Participants were recruited via email using a list of community
pharmacists provided by the Texas State Board of Pharmacy. All focus group discussions were structured using a moderator guide
consisting of both discrete and open-ended questions. Qualitative analysis software was used to analyze the data with a thematic
analysis approach.
Results: The participants in this study had a high self-efficacy regarding their ability to counsel on both new and opioid prescriptions.
Many pharmacists experienced the same barriers to counseling and agreed on the components of counseling. However, the themes
that emerged showed that the participants exhibited only a partial understanding of the components of counseling. The themes that
emerged in the thematic analysis were perceived confidence and discordant counseling practices, inadequate infrastructure, lack of
comprehensive counseling, inconsistent use of the Prescription Drug Monitoring Program (PDMP), and pharmacists’ desired
training/assistance.
Conclusions: Community pharmacists are in a unique position to help combat the opioid crisis; however, there has been very little
research on the pharmacist-patient interaction in this context. With policy changes, such as the PDMP mandate, going into effect
across the country, it is important to capitalize on the potential community pharmacists have in ameliorating the opioid crisis in the
United States.
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Counseling; Prescription Drug Misuse; Professional Practice; Pharmacies; Pharmacists; Prescription Drug Monitoring Programs; Opioid
Epidemic; Focus Groups; Texas

INTRODUCTION
In the 1990s, pharmaceutical companies began to promote
opioid medications as a safe method of treatment, with a
1
low addiction profile, for chronic or persistent pain. As a
2
result, opioid prescribing increased. While many people
can benefit from the pain management these medications
provide, the increase in prescriptions has increased rates of
diversion, misuse, dependency, and opioid use disorder
3,4
(OUD). In 2017, an estimated 1.7 million people within
5
the United States suffered from an OUD.
The severity of the opioid crisis has gained the attention of
federal agencies. The United States Department of Health
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and Human Services (HHS) declared the crisis to be a public
health emergency and outlined a 5-point plan to combat
6
it. The Agency for Healthcare Research and Quality (AHRQ)
released a Special Emphasis Notice committing to the HHS
7
mission to end the opioid crisis.
When discussing interventions to ameliorate the opioid
epidemic, community pharmacists are in a unique position
to aid in efforts to increase prevention as well as improve
access to effective treatment, recovery, and harm
reduction strategies. Not only are they the gatekeepers to
prescription medications with the ability to restrict access
to controlled substances, they are also consistently ranked
8-10
as one of the most trusted professionals.
Additionally,
pharmacists see their patients up to 10 times more than
primary care physicians – making them the most accessible
11
health care professional in the community. Their role
extends beyond simply filling and dispensing prescription
medications; they have a duty to provide counseling to
12,13
patients on the medications they fill.
Counseling plays
an even more important role for patients receiving
controlled substance prescriptions (CSP), as it is imperative
to provide safe usage, storage, and disposal information to
prevent misuse and diversion.
The Prescription Drug Monitoring Program (PDMP) is a tool
intended to aid community pharmacists. It is an electronic
database that provides a patient’s filling history of
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controlled substances across different pharmacies
14
regardless of payer. From March 1, 2020, Texas law will
mandate that every pharmacist in the state should check
the PDMP before dispensing a prescription for an opioid,
14
benzodiazepine, barbiturate, or carisoprodol. Having
access to a patient’s medication history of controlled
substances gives the pharmacist more insight into the
patient’s treatment, thereby guiding two clinical decisions –
whether to fill and how best to counsel the patient.
The majority of studies assessing the utilization of PDMPs
has focused almost entirely on the quantitative utilization
of the PDMP. For example, a study involving Indiana
pharmacists found that pharmacists who regularly used the
PDMP consistently were 3.3 times more likely to refuse to
fill a CSP compared to those who did not use the PDMP at
15
all. Both physicians and pharmacists have expressed the
opinion that the PDMP is burdensome and may
16
inappropriately reduce the number of opioids prescribed.
A recent study conducted in Kansas Medicaid patients
attributed the utilization of the state PDMP to difficulty in
17
obtaining a CSP in patients with chronic non-cancer pain.
There are additional studies that address this issue.
Pharmacists in Indiana also indicate that the perception of
a barrier will decrease PDMP utilization and pharmacists in
Kansas attributed “internet access” as the primary reason
18,19
for not using the PDMP.
Given the potential that pharmacists have in providing
interventions in the pharmacy setting, it is necessary to
understand the issue from their perspective. Research on
pharmacists’ willingness to counsel patients with a CSP
after reviewing the PDMP identified a total of 15
20
behavioral, 14 normative, and 11 control beliefs. While
pharmacists did acknowledge the benefit of counseling,
they still cited patient confrontation as the biggest
20
deterrent to engaging patients in the context of CSPs.
Other elicited beliefs extrapolated on the willingness of
pharmacists to engage with patients and has provided
much-needed insight into the pharmacist-patient
interaction. However, there has been little research into
the content of the interaction. Assessing and understanding
pharmacists’ counseling practices will assist in identifying
any barriers, reluctance, or gaps in counseling; and, in turn,
developing necessary educational interventions to address
these deficiencies. Ultimately, this knowledge will help
capitalize on the potential of community pharmacists in
efforts to mitigate the opioid crisis.
Therefore, the objective of this study was to assess
pharmacists’ practices when counseling patients on their
prescription medications, the barriers to counseling, and
their preferences for training.
METHODS
Study design and setting
This descriptive, qualitative study using focus group
discussions was intended to assess pharmacists’ practices
when counseling patients on their prescription
medications, the barriers they face, and their preferences
for training. The focus group discussions were held at an
agency that specializes in qualitative research located in a
major metropolitan city in the southern United States.

Participants and recruitment
The sample was generated via convenience sampling.
Pharmacists in the area were identified using the list of
actively licensed community pharmacists maintained by the
Texas State Board of Pharmacy (TSBP). Recruitment was
managed by the qualitative research group, who also
moderated and transcribed the focus group discussions.
While the inclusion criteria were limited to pharmacists
currently working in a community pharmacy setting, care
was taken to invite participants from a variety of retail
settings (i.e., mass merchandiser, retail chain, and
independent) to improve the generalizability of the results.
Of those invited, a sample of 45 pharmacists was generated
and divided into five different focus groups. Each focus
group had between 7 to 12 participants and lasted
between 90 and 120 minutes. Three focus groups were
initially scheduled, but two more were added as new ideas
were still being explored by the participants.
Prior to attending the focus groups, the participants were
given information about the study and informed consent.
To maintain the anonymity of the participants, minimal
demographic information was collected, and the
participants were asked to use their initials as their
pseudonyms. Participants were reimbursed USD 250 for
their time and effort. The study was approved by the
University of Houston Institutional Review Board.
Data collection
Two members of the research team created the moderator
guide which did not change between individual focus
groups (See Online appendix). The moderator guide
consisted of four sections, each with a point of emphasis
and a mix of discrete and open-ended questions. The initial
sections addressed prescription medications in general
while the latter narrowed the focus to opioid medications.
The first section contained the moderator’s introduction,
disclosures, and guidelines for the information collected,
and each participant’s introduction. The next section
focused on counseling on new prescriptions. Participants
were first asked to estimate the percentage of new
prescriptions they counsel on, followed by the reasons they
counsel, barriers to counseling, and their comfort level (on
a scale of one to five, with five being the greatest level of
comfort) on counseling for new prescriptions. The
participants were asked to respond according to their
current situation. Participants were also asked to elaborate
on the reasoning behind their comfort rating.
The third section of questions narrowed the conversation
to counseling on opioid medications. Similar to the
previous section, it started with a discrete question asking
participants to estimate the percentage of opioid
prescriptions they counsel. It then delved into asking them
to discuss their attitudes towards opioid medications when
prescribed in conjunction with other controlled substances,
barriers to counseling, and the components of counseling.
If the participants did not bring up safe storage, disposal,
and referral options, the moderator was instructed to ask
about them specifically. The final section of the moderator
guide focused on training preferences. It asked for
information regarding the following: whether the
pharmacists thought they required training, the content
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the training should cover, and the method or modality
through which the training should be offered.
Data analysis
Two research team members reviewed and initially coded
the focus group transcripts. A thematic analysis approach
was used to analyze the data. Thematic analysis is a
qualitative descriptive method used to identify and analyze
21
repeating patterns within a set of data. The research
team followed the established six steps for thematic
analysis:
1. Data Familiarization: Each member read the five focus
group transcripts independently without any a priori
assumptions and took notes on initial observations.
2. Generating Codes: The members met and discussed the
important aspects and relevant reoccurring themes in
the transcripts. Then, each member independently went
through the transcripts and created their own codes.
The two separate code lists were reconciled through
discussion between the research team members with a
faculty member serving as an arbitrator. This process
resulted in the final list of codes, also referred to as the
codebook.
3. Searching for Themes: Once the codebook was
generated, both members of the research team met to
organize the codes into overarching themes.
4. Reviewing Themes: Traditionally, this step would be
used to reconcile any differing themes and generate a
thematic map. In this study, the themes were discussed
and compiled together, so there was no need for
reconciliation. Additionally, the software used in this
study, ATLAS.ti© V722, can generate semantic
networks.
5. Defining and Naming Themes: Once the themes were
decided upon, the two members of the research team
responsible for the coding and the arbitrating faculty
member jointly reviewed and named the themes
appropriately.
6. Producing the Report: The final report consisted of the
coded, merged, and reconciled five transcripts along
with the codebook and themes.

participants were female and had worked in community
pharmacy for 10 years or longer (Table 1). All focus groups
were structured by the same moderator guide. Through the
thematic analysis process, five main themes emerged:
perceived confidence and discordant counseling practices,
Lack
of
comprehensive
counseling,
inadequate
infrastructure, pharmacists’ desired training/assistance,
and inconsistent use of the PDMP. These themes and their
corresponding codes are represented in a thematic map
(Figure 1). While all of the themes will be discussed in this
paper, please refer to Table 2 for examples of quotes for
each code.
Perceived confidence and discordant counseling practices
All participants across the five focus group discussions gave
a percentage above 80% for whether they counseled on a
new prescription. The participants’ percentages increased
to 90% or greater when discussing prescription opioids.
When asked to rate their comfort level with counseling,
pharmacists expressed high levels of comfort with
counseling on both new and opioid prescriptions. However,
further discussion revealed a discordance between their
confidence in their ability to counsel patients and their
actual practices. For example, when faced with the difficult
situation of denying a prescription to a patient, participants
varied in how they would handle it. Some indicated that
they would claim that they were out of stock rather than
explain why they were refusing to fill, and others said that
they would have no problem telling the patient why.
“I don't fret about it. I say, ‘it says that you got
some filled at this-and-this pharmacy at this date,
so you should have plenty and I'm not filling this
prescription.’” (Focus Group 1)
Throughout the rest of the discussion, participants
attributed the discrepancies between self-reported
confidence and practice to structural factors and the
inadequacy of the infrastructure around them. It also
became evident that some degree of the disconnect could
be accounted for by individual factors.
Inadequate infrastructure
When discussing new prescriptions, the most common
barriers to providing counseling were time constraints,
patient refusal of counseling, and language barriers.

RESULTS
In this study, five focus group discussions, totaling 45
pharmacists, were held in May 2018. The majority of
Table 1. Focus group participant demographic information (n=45)
Group 1
Group 2
Number of participants
7
10
Sex
Male
1
5
Female
6
5
Current Employer Type
Chain
3
3
Independent
4
7
Years of Experience
Less than 10 years
1
0
11-20 years
3
3
Greater than 20 years
3
7
Note: Focus groups were conducted in May 2018

“If I'm on the phone and they don't want to wait,
or they don't wait for me to go up to the register
and talk to them.” (Focus group 1)

Group 3
9

Group 4
11

Group 5
8

Total
45

5
4

3
8

2
6

16
29

5
4

6
5

5
3

22
23

1
4
4

1
4
6

3
3
2

6
17
22
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Figure 1. Map of themes and corresponding codes emerged from thematic analysis

“I had a patient who told me, ‘I know how to read,
I don't need you.’” (Focus Group 3)
“This is probably specific to my store. I have a
large Hispanic population. I do speak Spanish, but
I think some people in the Hispanic population
don't understand the concept of actually being
counseled. So, they walk off.” (Focus Group 1)
For opioid prescriptions specifically, respondents indicated
those same barriers, but also extrapolated on some others.
These include the patient perceiving the pharmacist as
accusing them of misuse and the pharmacists’ fear for their
own safety.
“And the other thing is how the patient may
perceive you counseling them on this particular
type of medication. They may feel like, "Well, why
are you talking to me about [the prescription]?
I'm not an addict.” (Focus Group 3)
“I don't argue with them. Most of the time, my
escape mechanism is, ‘I don't have it.’ Because I
don’t want to have a confrontation. I don’t want
you to wait for me after work. I've got two kids
I'm going home to.” (Focus Group 2)
Lastly, participants also expressed that much of the burden
of verifying misuse and limiting inappropriate misuse had
been left to them, thereby misaligning their role.

Lack of comprehensive counseling
The focus group discussions also revolved around a series
of questions regarding the pharmacists’ practices when
counseling on either a new prescription or an opioid
prescription. Initially, the moderator did not specify any
examples so as to not provide any leading questions.
During this time, there was a general lack of consensus on
the definition of a new prescription.
“Somehow when you said new prescriptions,
some of them said new prescription, but the
patient has been on it forever. Like some things
like that, it's not really new.” (Focus Group 2)
In contrast, the overemphasis of clinical factors was almost
unanimous. Participants elaborated on the side effects, the
indication, and the patient’s level of familiarity with the
medication. In the case of opioid prescriptions,
respondents expressed a strong awareness for the ongoing
opioid crisis, therefore, the potential for dependency and
misuse associated with these medications.
“I explain the use, because some drugs have
several uses. The most important thing [is] are
they allergic [or have had] any allergy reaction. I
explain to them the possible side effects.” (Focus
Group 3)
“Contraindications I feel they need to know
about, that kind of thing, and then I'll ask them if
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they have any questions, once I've done my legal
part.” (Focus Group 2)
“I will start with telling them the duration that the
doctor told them to take it, and I'll tell them that,
‘This is if you need it. You don't have to feel
mandatory to take it, because if you don't [need
it] you shouldn't take it.’” (Focus Group 2)
A few participants mentioned proper storage and disposal
of the medication unprompted, and when this occurred,
the moderator encouraged the group to elaborate further
on the topic. However, the majority of respondents
neglected to bring up storage and disposal as part of their

medication counseling. When this occurred, the moderator
specifically asked about these topics. This part of the
discussion yielded more inconsistencies in individual
awareness.
“You can't talk about disposal if there's no place
to dispose of it. Some states have them, Texas
does not. Not yet, and it says pharmacies can't beI mean, just imagine if I told everybody, ‘Bring me
your Vicodins that you don't want to take.’ I'd get
broken into that night.” (Focus Group 2)
In the context of prescription opioids, discussion of
counseling on storage included the potential for diversion

Table 2. Focus group discussions themes, corresponding codes, and example quotes
High Confidence in Ability to
“I do 100% on all the opioids because of the drowsiness possibility.” (Focus group 4)
Perceived
Counsel
Confidence and
“We already know that stuff. All that stuff that you just said, we already know or have
Discordant
Aversion to Training
incorporated into our day already. So to go and take a class on that, unless you're going
Counseling
to pay $250 like now, that's another story. I'll go to that class.” (Focus group 2)
Practices
“I don't fret about it. I say it says that you got some filled at this-and-this pharmacy at
Refusal to Fill Actions
this date, so you should have plenty and I'm not filling this prescription.” (Focus group 1)
Overemphasis of Clinical
“Contraindications I feel they need to know about, that kind of thing, and then I'll ask
Factors
them if they have any questions, once I've done my legal part.” (Focus group 2)
“You can't talk about disposal if there's no place to dispose of it. Some states have them,
Texas does not. Not yet, and it says pharmacies can't be-I mean, just imagine if I told
everybody, ‘Bring me your Vicodins that you don't want to take.’ I'd get broken into that
night.” (Focus Group 2)
Neglect of Safe
Storage/Disposal Information

Lack of
Comprehensive
Counseling

Lack of Awareness of Referral
Services

Variance in Definition of a
New Prescription

Sensitivity to Opioid Crisis

Pharmacist Safety

Time Constraint
Inadequate
Infrastructure
Language Barrier

“Now one thing I will discuss with patients [is] do not let any of your friends and family
know that you are on this medication, because they will steal their medications.” (Focus
group 1)
“They will break into your house and take it, or they will steal your purse if they know
you have it.” (Focus Group 4)
“Sometimes … I try to find something close by them or get them hooked up with a
doctor somewhere so they can get treated... We look-thank God for the internet.” (Focus
group 1)
“I didn’t do a referral. When I kicked a prescription, I called the doctor[s] and let them
[doctors] know I'm not filling that prescription and tell him or her how the patient is
acting. I leave it up to the doctor after that.” (Focus group 3)
The patient has been on the medication and does not need to be counseled. (Focus
group 2)
“They're spending the money. They're just spending it wrongly because I represented my
institution at [INAUDIBLE] for two straight weeks where we discussed addiction and we
had pharmacologists there. We had social studies people. We had MDs, we even had
MDs that were confessing right there as we sat around the bench telling their stories
about how they got over addiction. So that whole thing was sponsored by the NIH and
we were there for two weeks. That's really one of the reasons why I said it has to be a
holistic approach. If you keep dealing with one pocket at a time then there is no- So
they're spending the money, they’re just not connecting right, if you will.” (Focus group
4)
“I don't argue with them. Most of the time, my escape mechanism is, "I don't have it."
Because I don’t want to have a confrontation. I don’t want you to wait for me after work.
I've got two kids I'm going home to.” (Focus group 2)
“They don't want to wait after that.” (Focus group 1)
“If I'm on the phone and they don't want to wait, or they don't wait for me to go up to
the register and talk to them.” (Focus group 1)
“This is probably specific to my store. I have a large Hispanic population. I do speak
Spanish, but I think some people in the Hispanic population don't understand the
concept of actually being counseled. So, they walk off.” (Focus group 1)
“In my area, everybody speaks Spanish, but all my technicians speak Spanish and it's
totally fine. If it's Vietnamese, we have nobody who speaks Vietnamese.” (Focus group 5)

Infeasible to Engage All
Patients
Misaligned Role of Pharmacist

“I had a patient who told me, ‘I know how to read, I don't need you.’” (Focus group 3)
“If they would put the doctors on the front line with us.” (Focus group 1)
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Table 2 (cont.). Focus group discussions themes, corresponding codes, and example quotes
“I don't argue with them. Most of the time, my escape mechanism is, ‘I don't have it.’
Patients Suspected of Misuse
Because I don’t want to have a confrontation. I don’t want you to wait for me after work.
I've got two kids I'm going home to.” (Focus group 2)
“I have filled that combination for one patient whose history I know, but they also take a
whole lot of other medications because they have multiple mental health issues, physical
issues, and real disease states that are well beyond just like-also their diabetes
medication. They have a blood-clotting disorder. So I'm just like I know a whole lot about
this patient and it's not just oh, I'm coming in to just get the cocktail. So but that is really
Familiarity/Rapport
Inconsistent Use of
rare compared to just the people that come in for just those.” (Focus group 1)
PDMP
“Well, I have people who get it every month, and so I don’t check those, but even if they
get regular whatever medication and this is the first time they brought in an opioid, we
check. And if they’ve never been there, of course we check.” (Focus group 5)
“Sometimes you do probing questions, kind of by the feel of what they're there for:
‘Why are you taking it? Do you know how long you're going to be taking it? Did the doctor
Patient Knowledge
and you discuss that?’ And then after that, you tell them what they're taking and tell some
of the cautions of taking it, and especially in combination when they have more than one,
then you go into detail and tell them the risks that's involved in taking it.” (Focus group 3)
“The thing is, though, pharmacists are going to need beyond the education - will need the
support to implement. Because the bottom line is, we could - we're the most accessible
healthcare professionals. Tell a nurse, too. It's true, because they can find us in locations
like that. However, we've got a ton of work to do there. So, they're - that may be where
Support from Other
some of these new jobs need to be created for all the pharmacy [INAUDIBLE] they've
Stakeholders
created. And the pharmacists that are coming out and are running into challenging finding
Pharmacists’
work. So, in my mind, it's a number of different trainings. But it's a whole program,
Desired
because if this United States is in the epidemic, and it is an epidemic of drug abuse. Then
Training/Assistance
why should we not focus on something like that to make a difference in the lives of people
in our country.” (Focus group 5)
“The most important thing is what you see on a daily basis. That on the-job training is the
On the Job Training
best kind.” (Focus group 1)
“Narcan so that we have a better understanding that we can counsel and teach the
Advocacy for Patients
patients and caregivers, like you were talking about earlier” (Focus group 5)

and the need to prevent others from accessing their CSP.
“Now one thing I will discuss with patients [is] do
not let any of your friends and family know that
you are on this medication, because they will steal
their medications.” (Focus Group 1)
“They will break into your house and take it, or
they will steal your purse if they know you have
it.” (Focus Group 4)
When asked about what pharmacists do when they
encounter a patient who they suspect of experiencing an
opioid dependency or at risk for one, participants exhibited
an overall lack of awareness regarding referral services. As
a result, they often resort to other methods to get their
patient the help they need.
“Sometimes … I try to find something close by
them or get them hooked up with a doctor
somewhere so they can get treated... We lookthank God for the internet.” (Focus Group 1)
“I didn’t do a referral. When I kicked a
prescription, I called the doctor[s] and let them
[doctors] know I'm not filling that prescription and
tell him or her how the patient is acting. I leave it
up to the doctor after that.” (Focus Group 3)
Inconsistent use of the PDMP
When participants were asked what they consider to be
signs of misuse, the conversation turned to the usage of
PDMPs. Respondents did confirm the PDMP to be a helpful
tool in their decision-making process when suspecting
misuse. However, they also revealed that they were

inconsistent in which patients they reviewed. Familiarity or
rapport with the patient was associated with usage of the
PDMP, as was the level of knowledge a patient had
regarding their medication, clinical indication, and the
pharmacy. The PDMP in Texas is called the Prescription
Monitoring Program (PMP).
“Well, it would have to-I would have to see-really
what helps me to make my decision is what I
looked at and find in PMP. And basically, I had a
gentleman and I didn't fill his prescription because
I really thought first of all, there's no way you're
taking all these, and who in the world is giving
you-this has got to be a trap from the state
board.” (Focus Group 2)
“Well, I have people who get it every month, and
so I don’t check those, but even if they get regular
whatever medication and this is the first time they
brought in an opioid, we check. And if they’ve
never been there, of course we check.” (Focus
Group 5)
Pharmacists’ desired training/assistance
The final point of discussion for each focus group was their
preferences for further training. The moderator outlined
two training components – knowledge on controlled
substance medications or training on communication skills
– and asked who would be interested in one or both
options for training. The participants had mixed responses
overall. Those that were interested in training were asked
to further elaborate on what the training should consist of
and how they would prefer the training to be administered.
Those that were not interested claimed that outside
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training would not be beneficial because the only effective
way for new pharmacists to learn would be to gain
experience on the job.
“We already know that stuff. All that stuff that
you just said, we already know or have
incorporated into our day already.” (Focus Group
2)
The most common training components asked for were
information on new and existing medications, potential
signs of misuse, and assistance in communication with
patients.
“[Someone] was saying it's obvious when
someone was abusing, for me it's actually not that
obvious. I have to use the red flags.” (Focus Group
1)
“… I want something that's geared toward me,
community pharmacy, and – ‘Hey, look. These are
the common new cocktails. This is what you can
do for this.’ Because my knowledge on Suboxone
and Methadone, I'm embarrassed, but it's
lacking.” (Focus Group 5)
Participants that did not want training expressed a desire
for more involvement or changes in practice from other
health care stakeholders to alleviate the burden on them.
“I think the other thing is the insurance
companies. They should require the patients
themselves, to have [to watch] a video, about
what they have prescribed for them. It [the video]
talks about the opioid crisis maybe in general and
not so much as counseling, it just talks about what
this medication can actually do if taken in the
wrong way. Just kind of give them a heads up. So
when we [pharmacists] do approach them,
they're more comfortable with [having] the
conversation with their pharmacist.” (Focus
Group 3)
When asked for their preferred modality to receive
training, participants’ answers varied, with no general
consensus for any singular training modality. However,
participants did bring up the helpfulness of a tangible
resource when counseling.
“I remember when I was at Walgreens, they did a
sheet and I read it once, and it was pretty decent.
It was step by step, [of] what to do, how to
approach the patient, [and] what to say. It was
really good. It told you even how to say I'm not
comfortable filling this prescription. So one sheet
like that you read over it would be fine.” (Focus
Group 1)
DISCUSSION
From this study, the most pervasive theme was the
discordance between the pharmacists’ self-reported
confidence in their ability to counsel and the counseling
practices they exhibited. Participants reported that they
counseled on 80% or greater of all new prescriptions and
that they were very comfortable when counseling on them.
A new prescription in Texas is formally defined as “a

prescription drug order that has not been dispensed to the
patient in the same strength and dosage form by this
12
pharmacy within the last year”. In the focus groups,
participants debated on what they would consider to be a
new prescription. Some claimed that if the patient had
never been on the medication before, then it was a new
prescription. Others stated that if the patient had been on
the medication previously, but the prescription was
renewed, then it should be considered a treated as a new
prescription. Variability in the definition of a new
prescription could potentially create inconsistencies in
when pharmacists counsel patients on their medication.
For example, a participant that states that they counsel on
80% of new prescriptions may seem as if they are
counseling consistently as face value. However, if their
definition of a new prescription is much narrower than the
legal definition, they may not be counseling as frequently
as they’re expected to.
In the case of counseling a patient with an opioid
prescription, participants reported even higher percentages
(>90%) for when they counsel, and that they were equally
or more comfortable counseling on an opioid prescription
as they were with any new prescription. However, further
discussion elicited beliefs contradictory to comfort with
patients filling an opioid medication. When discussing
barriers to counseling, participants cited structural issues
such as time constraints, language barriers, and in the
context of opioids, pharmacist safety. The last concern led
to some pharmacists feeling that “If they're abusing, I don't
want them to come back” (Focus Group 4). Their fears were
not completely unfounded, since many of the participants
knew pharmacists who had faced potentially threatening
situations when interacting with a patient filling a CSP.
Negative behavioral beliefs among pharmacists towards
engaging patients suspected of misusing CSPs has been
20
well-documented. It is also important to note that
patients with OUD have expressed fear of judgement or
retaliation while they attempt to seek treatment or
23
recovery options through community pharmacies. The
participants in the focus group discussions also mentioned
their hesitance to pull aside a patient with an opioid
prescription for counseling for fear of being perceived as
accusatory.
When asked what could be done to alleviate this burden on
them, many of them cited more involvement from other
health care stakeholders. One participant suggested that
the situation would improve, “If they would put the doctors
on the front line with us” (Focus group 1). The factors
mentioned above could be attributed to a general lack of
sufficient structural and organizational support, thereby
hindering pharmacists from fulfilling their roles as
advocates for the health of the communities they serve.
However, it is also important to recognize that even if these
hindrances were addressed, there are still individual-level
factors that prevent pharmacists from delivering
comprehensive counseling.
When the moderator asked what the participants
counseled on once they decide to do so, participants
exhibited an overemphasis on the clinical factors. Very few
participants brought up storage and disposal on their own.
According to the TSBP, counseling a patient on a
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medication should include safe usage, storage, and disposal
12
of the medication. If the medication is a controlled
substance, then the pharmacist should also discuss the
potential for diversion, the risk for misuse, and potential
referral services the patient could go to for more
12
information or help. Time constraints have been cited as
the most common control belief preventing them from
counseling, and could be the primary reason why
pharmacists are unable to cover all of the components of
20
counseling with each patient. However, it is also possible
that pharmacists may not have a clear knowledge base
regarding what options are available to discuss with
patients. This possibility came to light when discussing safe
disposal and referral options. As seen in the results, the
moderator asked the participants if they were aware of
drug deactivation devices, such as Deterra® or DisposeRx®.
Most participants in the focus groups were unaware of
24
them, in line with previous research.

health care stakeholders. They specifically named insurance
companies, physicians, and their employers as entities that
need to be more involved in efforts to ameliorate the
opioid crisis. Improved communication between
pharmacists and other stakeholders can alleviate the
burden on pharmacists. The disconnect between
pharmacists and physicians cause pharmacists to make
decisions about the patient care while lacking important
27
health information. Access to the PDMP has reduced this
issue, but in order to resolve it, there needs to be a better
flow of information between the pharmacist and physician.
One possible solution to this is to consider the idea of
increased Electronic Health Record (EHR) interoperability to
include PDMP databases, so that pharmacists have access
to the same clinical information that physicians are privy to.
More importantly, this integration would also lessen the
chasm between physicians and pharmacists and unite them
in their efforts to address the opioid epidemic.

Another individual-level factor that lead to a lack of
comprehensive counseling was the inconsistency with
which the pharmacists used the PDMP. PDMPs are statemaintained electronic databases that track controlled
prescription medication fill history. They can be important
tools when looking for signs of misuse, but their potential is
squandered when not used consistently, or if the reasoning
behind reviewing patients is arbitrary.

In concordance with previous studies, community
pharmacists feel that the TSBP and the supervisors directly
overseeing them have a great deal of influence over their
29
daily practices within the pharmacy. Given this, offering
training as a requirement from the TSBP or their employer
may be the best way to ensure all pharmacists are trained
properly on how to counsel on controlled substance
prescriptions. Another possible setting for intervention,
especially with student pharmacists, would be to
implement change to the curriculum for the gaps identified.
To comply with the opinion that on the job training would
be the most effective modality, the training should consist
of a series of simulations. These simulations should
emulate real-world situations that pharmacists could face.

Familiarity and rapport with the patient can be beneficial
when a patient is suffering from OUD and the pharmacist
feels comfortable enough to have a conversation with that
patient. However, this relationship seems to hinder the
pharmacist’s judgment when it comes to reviewing them in
the PDMP. One pharmacist claimed that they would not
check the PDMP for a patient they see on a regular basis.
On the other hand, a lack of familiarity and rapport with a
patient seems to encourage pharmacists to ask more
questions from the patient. At the surface level, this seems
to be a better practice than being lenient on patients they
are familiar with; however, this may also be a detrimental
practice. While patient knowledge of their disease state
was an indicator of legitimate use for some pharmacists,
other pharmacists indicated that a patient that knew too
much about the medication was probably misusing.
Familiarity or rapport with the patient seems to reduce
stigma for patients attempting to receive treatment, but it
should not be the primary consideration in a pharmacist’s
decision to dispense a medication.
Pharmacists also described that they feel as if they’ve been
on the “front lines” of the opioid epidemic. There is merit
to this assertion since pharmacists are responsible for
23,25
deciding whether to fill and dispense any prescription.
While physicians often have the hospital, nurses, and other
physicians working in close proximity to them, community
pharmacists are more isolated. Even those who use the
PDMP don’t always have the same information that the
prescribing physician does (e.g., diagnosis, source of pain).
In this situation, the pharmacist can contact that physician,
but this approach has mixed results, due to difficulty
getting in contact with the prescriber.
In the final part of the focus group discussions, participants
were asked what kind of training they would benefit from.
Respondents outlined a need for involvement from other

Limitations
Participation in this study was limited to community
pharmacists in a large metropolitan area in the southern
United States, which may introduce selection bias. The
majority of participants in this study self-reported 10+
years of experience, so it is possible that some of the
pharmacy practice information shared by these participants
may not align with the current best practice
recommendations. Limited demographic information was
collected, which may limit the ability to interpret findings.
Furthermore, participants in this study were not asked to
recall information over a certain period of time, so this can
lead to recall bias due to participants not remembering
accurately or omitting details. Lastly, some participants in
this study proved to be more vocal and willing to share
their opinions, so social desirability may have suppressed
some opposing viewpoints.
CONCLUSIONS
This study furthers our understanding of the pharmacistpatient interaction, thereby allowing us to identify gaps in
current practices. To improve this relationship, training
interventions need to be designed to allow for more
comprehensive counseling on prescription medications.
The training interventions should be geared towards
offering services that address language barriers, training
pharmacists on how to more effectively engage patients in
need of counseling and increasing pharmacy support staff
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in order to increase the availability of the pharmacist to
patients.
While this study has provided valuable insight into an
ongoing issue, there is still further need for research in key
areas: (1) identifying the most effective forms of
educational interventions to address the overall lack of
awareness pharmacists exhibited in comprehensive
counseling practices; (2) specific gaps in communication
between the pharmacist and prescriber need to be
identified and a better mode of information transfer needs
to be designed, potentially through EHR interoperability.
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